|
In the Treatment of Asthma, Merck's Singulair Accounts for More Than a Quarter …
MarketWatch (press release) Analysis of US patient-level claims data from Treatment Algorithms in Asthma also finds that more than half of newly diagnosed asthma patients that move to the second line of therapy within a year of diagnosis are treated with Singulair. … |
View full post on asthma – Google News